The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients ( TROPHIES ): Final patient‐reported outcomes at 24 months
Authors' conclusion
Improvements in PROs observed in TROPHIES, which were more evident with dulaglutide than liraglutide, reflect a relevant clinical benefit. From the patients' perspective, satisfaction, and confidence in continuing treatment with GLP-1RAs is likely to contribute to long-term treatment persistence.
Study context
- Population
- Adults with T2D, naïve to injectable treatment, prescribed dulaglutide or liraglutide as first injectable glucose-lowering medication (GLM); France, Germany and Italy
- Exposure
- Dulaglutide vs liraglutide as first injectable GLM
- Outcome
- Patient-reported outcomes (PROs): health-related quality of life; impact of weight on self-perception; life and work productivity; satisfaction with treatment and injection device
- Follow-up
- 24 months
Methodological detailstwo-cohort, real-world, France, Germany and Italy
- Two-cohort
- Real-world
- France, Germany and Italy
Main finding
As reported in the abstract
PRO scores
- Improvements from baseline in PRO scores with dulaglutide or liraglutide
- More pronounced improvement with dulaglutide in treatment satisfaction and impact of weight on self-perception; statistically significant differences between cohorts at 12, 18 and 24 months
- More positive perceptions of the injection device with dulaglutide than liraglutide
Observational data: associations, not effects.
Original publication
The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients ( TROPHIES ): Final patient‐reported outcomes at 24 months. Diabetes Obes Metab. Published 15 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →